The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography

Alhasan Mujtaba Abdul-Wahid

Status and phase: Completed; Phase 2

Conditions: IHD; Acute Kidney Injury; Contrast-induced Nephropathy

Treatments: Drug: Spironolactone; Drug: Placebo Oral Tablet

Study type: Interventional

Funder types: Other

Identifiers

NCT03329443

CT00964

Details and patient eligibility

About

an interventional study to measure the possible effects of spironolactone ( an aldosterone antagonist) on the incidence of acute kidney injury after coronary angiography

Enrollment: 490 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients admitted to angiography unit
• over 18
• informed consent

Exclusion criteria

• acute renal failure before 7 days
• spironolactone contraindications
• hyperkalemia (S.K. >5.5 mEq/L)
• documented tumor
• actively taking NSAIDs, Ciclosporin, Cisplatin,

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

490 participants in 2 patient groups, including a placebo group

placebo

Placebo Comparator group

Treatment:

Drug: Placebo Oral Tablet

Spironolactone

Active Comparator group

Treatment:

Drug: Spironolactone